COPD Treatment is Finally Changing
After a COPD flare-up, the risk of future, damaging flare-ups increases even with medication. A new outpatient COPD clinical trial may finally help reduce this risk.
See if You Qualify
Now Enrolling – AIRFLOW-3 COPD Clinical Trial
The AIRFLOW-3 Clinical Trial is evaluating the dNerva® Lung Denervation System, an investigational device in North America. This one-time, non-surgical treatment targets problems in the airways and may reduce the risk of future COPD flare-ups.
Short treatment that takes about 60 minutes
Treatment delivered through a standard bronchoscope
Outpatient procedure with most patients returning home the same day
No cost to participate and reimbursement for travel expenses to attend study visits
The study is currently enrolling patients in the United States and Europe.
COPD Exacerbations are the Problem.
Be a Part of the Solution.
The AIRFLOW-3 Clinical Trial is the first interventional COPD trial targeting exacerbation risk reduction in patients on optimal drug therapy.